Such changes would occur mostly likely near or in the active binding site of the enzyme.
Because the drugs used are competitive inhibitors of the <span>HIV reverse transcriptase enzyme, it means that they connect directly to the active binding site of this enzyme not allowing it to preform its function. If the mutations impede this drugs to work, it is probably because they alter the active binding site of the enzyme, not allowing the drug to bind and have its competitive behaviour permitting the enzyme to work normally. </span><span /><span>
</span>
In order to "invest" in later stages to get more energy per glucose molecule. It could also be because that is how it is done, it wouldn't be as efficient unless these stages were performed.
hope this helps!
